The company warned, in issuing its second quarter financial results Tuesday, that "total operating expenses will be higher than previously forecast and year-end cash will be lower than previously forecast" due to the stepped-up efforts to commercialize BiDil. All of this activity is taking place even though more detailed clinical test results won't be available until the fourth quarter. Loberg said the results will be added to the company's application to the Food and Drug Administration.